The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Phase 3positiveDeramiocelPositive
AI Analysis
Summary
Capricor Therapeutics' deramiocel met the primary endpoint in the Phase 3 HOPE-3 trial for Duchenne Muscular Dystrophy, slowing upper limb function decline by 54% versus placebo with clinically meaningful cardiac benefit. The results were published in The Lancet with independent peer review validation.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Patients
106
Outcome Details
HOPE-3 Phase 3 trial met primary endpoint, slowing upper limb function decline by 54% versus placebo (PUL 2.0, p=0.03) with clinically meaningful cardiac benefit
Importance:8/10
Sentiment:
0.85
Phase 3 dataDMDprimary endpoint metLancet publicationpeer-reviewed
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 29, 2026 2:05 PM